Hubei Jumpcan Pharmaceutical Co., Ltd.
600566
Rank in Stocks
#4335
Hubei Jumpcan Pharmaceutical Co., Ltd. is a Chinese enterprise dedicated to the... Hubei Jumpcan Pharmaceutical Co., Ltd. is a Chinese enterprise dedicated to the full spectrum of pharmaceutical operations, encompassing research, development, production, and marketing. The company's product lines include both traditional Chinese and Western medicines, as well as daily-use chemical products incorporating traditional Chinese medicine, and health supplements rooted in Chinese medical practices. Their diverse range of Chinese and Western pharmaceuticals addresses a wide array of therapeutic areas, such as pediatric care, women's health, respiratory conditions, digestive disorders, and geriatric medicine. Additionally, their development pipeline covers treatments for detoxification, nervous system ailments, anti-infective agents, cardiovascular issues, pain relief, nutritional deficiencies, musculoskeletal problems, and blood clotting management. Beyond medicinal products, Jumpcan also manufactures oral and skin care items. The company's Chinese medicine-based health products are designed to provide benefits like fatigue reduction, anti-aging effects, antioxidant support, and immune system boosting. Headquartered in Taixing, China, the company adopted its current name, Hubei Jumpcan Pharmaceutical Co., Ltd., in March 2015, having previously operated as Hubei Hongcheng General Machinery Co., Ltd.
Share Price
$3.87
Market Cap
$3.57B
Change (1 day)
-1.64%
Change (1 year)
9.08%
Country
CN
Trade Hubei Jumpcan Pharmaceutical Co., Ltd. (600566)
Category
Healthcare
Earnings for Hubei Jumpcan Pharmaceutical Co., Ltd. (600566)
Earnings in 2026 TTM: 0
According to Hubei Jumpcan Pharmaceutical Co., Ltd. latest financial reports the company's current earnings are 0. In 2026 the company made an earning of 0, equal to its 2026 earnings that were of 0. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for Hubei Jumpcan Pharmaceutical Co., Ltd. from 2001 to 2026
Earnings at the end of each year
| Year | Earnings | Change |
|---|---|---|
| 2025 | $309.05M | -24.26% |
| 2024 | $408.03M | -12.40% |
| 2023 | $465.78M | 28.11% |
| 2022 | $363.58M | 18.48% |
| 2021 | $306.87M | 35.13% |
| 2020 | $227.09M | -16.47% |
| 2019 | $271.87M | -5.40% |
| 2018 | $287.38M | 30.25% |
| 2017 | $220.64M | 40.80% |
| 2016 | $156.70M | 27.27% |
| 2015 | $123.13M | 26.13% |
| 2014 | $97.62M | 27.38% |
| 2013 | $76.64M | 66.50% |
| 2012 | $46.03M | 3,404.74% |
| 2011 | $1.31M | -0.73% |
| 2010 | $1.32M | 15.79% |
| 2009 | $1.14M | -13.96% |
| 2008 | $1.33M | -42.34% |
| 2007 | $2.30M | 28.76% |
| 2006 | $1.79M | 27.84% |
| 2005 | $1.40M | 13.48% |
| 2004 | $1.23M | -0.48% |
| 2003 | $1.24M | -50.58% |
| 2002 | $2.51M | -0.21% |
| 2001 | $2.51M | 0.00% |
Earnings for similar companies or competitors
| Company | Earnings | Earnings Difference | Country |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | - |
IN
|
